B
Bull
Bull · 25%TERN
$5.84
情境價格
$52.950
+0.021 (+0.04%)收盤時
Loading chart…
- High
- 52.980
- Open
- 52.970
- VWAP
- 52.96
- Vol
- 6.35M
- Mkt Cap
- 459.85M
- Low
- 52.940
- Amount
- 336.12M
- EV/EBITDA, TTM
- 0.00
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its product candidates in pipeline includes TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic dysfunction-associated steatohepatitis (MASH). It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.
AI analysis of Terns Pharmaceuticals Inc (TERN)
holdTerns Pharmaceuticals Inc (TERN) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The lack of significant positive catalysts, neutral trading sentiment, and limited financial growth trends suggest holding off on this stock for now.
估值指標
The current forward P/E ratio for Terns Pharmaceuticals Inc (TERN) is 0.00, compared to its 5-year average forward P/E of -5.11.
Alphio AI Price Scenarios for TERN
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding TERN
事件時間軸
資訊
9.507-30stocktwitsViking Therapeutics Q2 Earnings Report Analysis
8.506-05stocktwitsPharmaceutical Giants Accelerate Acquisitions to Offset Patent Cliffs
6.005-28stocktwitsTruist Initiates Coverage on VKTX with Buy Rating and $83 Price Target
9.004-27NewsfilterTerns Receives FDA Breakthrough Therapy Designation for TERN-701
4.004-27moomooTERNS PHARMACEUTICALS INC.: OPPENHEIMER LOWERS RATING TO PERFORM FROM OUTPERFORM
TERN FAQ — answered by Alphio AI
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its product candidates in pipeline includes TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic dysfunction-associated steatohepatitis (MASH). It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Terns Pharmaceuticals Inc (TERN) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The lack of significant positive catalysts, neutral trading sentiment, and limited financial growth trends suggest holding off on this stock for now.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。